ONC.L
Oncimmune Holdings plc [ONC.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ONC.L Stock Summary
In the News
ONC.L Financial details
Company Rating
-
Market Cap
17.45M
Income
-125.5K
Revenue
1.41M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
26 May 2023
P/E
-3.78
Forward P/E
-
PEG
0.42
P/S
5.4
P/B
3.35
P/C
-
P/FCF
-3.59
Quick Ratio
0.88
Current Ratio
1.64
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-137.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
46.45%
Revenue Q/Q
-97.51%
EPS Q/Q
-289.66%
-
-
-
-
SMA20
-99.38%
SMA50
-99.92%
SMA100
-99.94%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-184%
ROC
-0.35%
Gross Margin
77%
Oper. Margin
-138%
Profit Margin
-124%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.0-45.0
52W High
-99.97%
52W Low
-99.91%
RSI
16.92
Rel Volume
-
Avg Volume
65.51K
Volume
Perf Week
0%
Perf Month
-99.49%
Perf Quarter
-
Perf Half Y
-99.93%
-
-
-
-
Beta
0.495164
-
-
Volatility
0%, 0.87%
Prev Close
0%
Price
0.0114
Change
0%
Company Profile
- Volume Average 65.51K
- Market Capitalization 17.45M
- Employee 52
- CEO Dr. Adam Mark Hill Ph.D.
- Headquarters Nottingham,GB
- IPO Date 2016-05-18
-
Website
https://www.oncimmune.com 
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
